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Rationale Early reperfusion in patients experiencing acute isch-
emic stroke is critical, especially for patients with large vessel
occlusion who have poor prognosis without revascularization.
Solitaire™ stent retriever devices have been shown to immedi-
ately restore vascular perfusion safely, rapidly, and effectively
in acute ischemic stroke patients with large vessel occlusions.
Aim The aim of the study was to demonstrate that, among
patients with large vessel, anterior circulation occlusion who
have received intravenous tissue plasminogen activator, treat-
ment with Solitaire revascularization devices reduces degree
of disability 3 months post stroke.
Design The study is a global multicenter, two-arm, prospective,
randomized, open, blinded end-point trial comparing func-
tional outcomes in acute ischemic stroke patients who are
treated with either intravenous tissue plasminogen activator
alone or intravenous tissue plasminogen activator in combina-
tion with the Solitaire device. Up to 833 patients will be
enrolled.
Procedures Patients who have received intravenous tissue
plasminogen activator are randomized to either continue with
intravenous tissue plasminogen activator alone or additionally
proceed to neurothrombectomy using the Solitaire device
within six-hours of symptom onset.
Study Outcomes The primary end-point is 90-day global dis-
ability, assessed with the modified Rankin Scale (mRS). Second-
ary outcomes include mortality at 90 days, functional indepen-
dence (mRS ≤ 2) at 90 days, change in National Institutes of
Health Stroke Scale at 27 h, reperfusion at 27 h, and thromboly-
sis in cerebral infarction 2b/3 flow at the end of the procedure.
Analysis Statistical analysis will be conducted using simulta-
neous success criteria on the overall distribution of modified
Rankin Scale (Rankin shift) and proportions of subjects achiev-
ing functional independence (mRS 0–2).
Key words: acute ischemic stroke, clinical trial, endovascular,
recanalization, stent retriever, thrombolysis
Introduction
Stroke is the second leading cause of death and a leading cause of
disability worldwide (1). Cerebral infarction, due to thrombotic
occlusion of a brain artery, is the most common stroke type,
accounting for 65–85% of all cases. The only specific therapy of
demonstrated benefit for acute ischemic stroke (AIS) is intrave-
nous (IV) fibrinolysis with tissue plasminogen activator (tPA) up
to 4·5 hours after onset. However, patients with occlusions of
large, proximal, intracranial arteries are often not responsive to IV
tPA, as lytic therapy achieves early reperfusion in only 13–50% of
patients with occlusions in the carotid terminus and the M1
segment of the middle cerebral artery (MCA) (2–5).
The Solitaire™ Flow Restoration (FR) device is a self-expanding
stent retriever that restores blood flow in patients experiencing
ischemic stroke because of large intracranial vessel occlusion. In
multicenter registries and large clinical series, the Solitaire stent
retriever has yielded high rates of reperfusion and favorable clinical
outcomes (6–8). In a randomized, head-to-head device trial, com-
pared with first-generation, coil retriever devices, use of the Soli-
taire™ FR was associated with superior recanalization rates, faster
achievement of reperfusion, reduced intracranial haemorrhage
complications, and improved final disability outcome (9).
The Solitaire™ with the Intention for Thrombectomy as
Primary Endovascular Treatment for Acute Ischemic Stroke
(SWIFT PRIME) trial is being undertaken to establish the safety
and efficacy of neurothrombectomy with Solitaire in conjunction
with IV tPA vs. IV tPA alone, among AIS patients treatable within
six-hours of symptom onset.
Methods
Objective
The aim of this study is to determine whether subjects experienc-
ing an AIS due to large vessel occlusion treated with combined IV
tPA and Solitaire revascularization device within six-hours of
symptom onset have less stroke-related disability than those sub-
jects treated with IV tPA alone.
Design
The study is a global, multicenter, two-arm, prospective, random-
ized, open, blinded end-point clinical trial. The study patient flow
outline is shown in Fig. 1.
Patient population
Entry criteria were structured to enroll patients who have AIS,
moderate to severe neurologic deficits, harbor imaging-
confirmed occlusions of proximal, anterior circulation arteries,
do not have a large, established core infarct, have received treat-
ment with IV tPA, and are able to undergo Solitaire neurothrom-
bectomy within six-hours of last known well time. Full, detailed
study inclusion and exclusion criteria are shown in Table 1.
During the course of the trial, a revision in imaging entry
criteria was made. At launch, the study employed a ‘target mis-
match’ strategy, using multimodal computed tomography (CT)
or magnetic resonance imaging (MRI), including perfusion
sequences, to identify patients with salvageable tissue (10). Sub-
sequently, to accommodate sites with limited perfusion imaging
capability and ensure accelerated treatment delivery (11), Revi-
sion F of the study changed imaging entry criteria to employ a
‘small to moderate core’ strategy, using Alberta Stroke Program
Early CT score (ASPECTS) ratings of CT or magnetic resonance
(MR) images (12).
At sites in which standard imaging practice includes CT or MR
angiography (MRA) (and, under the initial study entry criteria,
perfusion imaging), patients may directly be enrolled in the ran-
domized phase of the trial. At sites where this imaging is not
standard practice, subjects are first enrolled in a screening phase
and the imaging studies are obtained. A subject is considered
enrolled into the screening phase of the study after the informed
consent form has been signed or country-specific requirements
have been met for enrollment without explicit informed consent
in emergency circumstances. A subject is considered enrolled in
the randomized phase of the study after a treatment allocation is
assigned from the randomization system.
Randomization
Subjects will be randomly assigned in a 1 : 1 fashion to one of two
treatment arms: (1) IV tPA and Solitaire device or (2) IV tPA
alone. The number of treatments and controls will be balanced
within investigational sites and by baseline National Institutes of
Health Stroke Scale (NIHSS) severity (≤17 vs. >17), age (<70 years
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Fig. 1 Study design diagram. ASPECTS, Alberta Stroke Program Early CT score; CTA, computed tomography angiography; CTP, computed tomography
perfusion imaging; DWI, diffusion-weighted imaging; FLAIR, fluid attenuated inversion recovery; FR, Flow Restoration; GRE, gradient refocused echo;
IV, intravenous; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NCCT, non-contrast CT; PWI, perfusion weighted imaging;
tPA, tissue plasminogen activator.
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Table 1 Study inclusion and exclusion criteria
Inclusion criteria:
1. Age 18 – 80
2. Clinical signs consistent with acute ischemic stroke
3. Prestroke Modified Rankin Score ≤ 1
4. NIHSS ≥ 8 and < 30 at the time of randomization
5. Initiation of IV tPA within 4·5 hours of onset of stroke symptoms (onset time is defined as the last time when the patient was witnessed to
be at baseline), with investigator verification that the subject has received/is receiving the correct IV tPA dose for the estimated weight prior
to randomization.
6. Thrombolysis in cerebral infarction (TICI) 0–1 flow in the intracranial internal carotid, M1 segment of the MCA, or carotid terminus confirmed
by CT or MR angiography that is accessible to the Solitaire™ FR device. (Note: M1 segment of the MCA is defined as the arterial trunk from
its origin at the ICA to the first bifurcation or trifurcation into major branches neglecting the small temporo-polar branch.)
7. Subject is able to be treated within six-hours of onset of stroke symptoms and within 1·5 hours (90 min) from CTA or MRA to groin
puncture.
8. Subject is willing to conduct protocol-required follow-up visits.
9. An appropriate signed and dated informed consent form (or enrollment under exception from explicit informed consent if permitted under
country regulations)
10. Subject is affiliated with a social security system (if required by individual country regulations).
11. Subject meets national regulatory criteria for clinical trial participation.
Exclusion criteria:
1. Subject who is contraindicated to IV tPA as per local national guidelines.
2. Female who is pregnant or lactating or has a positive pregnancy test at time of admission.
3. As applicable by French law, subject who is a protected individual such as an incompetent adult or incarcerated person.
4. Rapid neurological improvement prior to study randomization suggesting resolution of signs/symptoms of stroke
5. Known serious sensitivity to radiographic contrast agents
6. Known sensitivity to nickel, titanium metals, or their alloys
7. Current participation in another investigation drug or device treatment study
8. Known hereditary or acquired haemorrhagic diathesis, coagulation factor deficiency. (A subject without history or suspicion of coagulopathy
does not require INR or prothrombin time lab results to be available prior to enrollment.)
9. Renal failure as defined by a serum creatinine > 2·0 mg/dl (or 176·8 μmol/l) or glomerular filtration rate (GFR) < 30.
10. Subject who requires hemodialysis or peritoneal dialysis, or who has a contraindication to an angiogram for whatever reason.
11. Life expectancy of less than 90 days
12. Clinical presentation suggests a subarachnoid haemorrhage, even if initial CT or MRI scan is normal
13. Suspicion of aortic dissection
14. Subject with a comorbid disease or condition that would confound the neurological and functional evaluations or compromise survival or
ability to complete follow-up assessments.
15. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than four
alcoholic drinks per day).
16. Known history of arterial tortuosity, preexisting stent, and/or other arterial disease that would prevent the device from reaching the target
vessel and/or preclude safe recovery of the device
Imaging exclusion criteria
1. CT or MRI evidence of haemorrhage on presentation
2. CT or MRI evidence of mass effect or intra-cranial tumour (except small meningioma)
3. CT or MRI evidence of cerebral vasculitis
4. CT showing hypodensity or MRI showing hyperintensity involving greater than 1/3 of the MCA territory (or in other territories, > 100 cc of
tissue) on presentation
5. *Baseline non-contrast CT or DWI MRI evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke
Program Early CT score (ASPECTS) < 6.
6. CT or MRI evidence of a basilar artery (BA) occlusion or posterior cerebral artery (PCA) occlusion
7. CTA or MRA evidence of carotid dissection or complete cervical carotid occlusion requiring stenting at the time of the index procedure (i.e.
mechanical thrombectomy)
8. Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention
(e.g. inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.).
*Before Revision F, this criterion stated: ‘Core Infarct and hypoperfusion: a) MRI- or CT-assessed core infarct lesion greater than 50 cc; b) Severe
hypoperfusion lesion (10 sec or more Tmax lesion larger than 100 cc); c) Ischemic penumbra < 15 cc and mismatch ratio ≤1·8’.
CT, computed tomography; CTA, computed tomography angiography; DWI, diffusion-weighted imaging; ICA, internal carotid artery; INR, interna-
tional normalized ratio; IV, intravenous; MCA, middle cerebral artery; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging;
NIHSS, National Institutes of Health Stroke Scale; tPA, tissue plasminogen activator.
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vs. ≥70 years at the time of randomization), and occlusion loca-
tion (M1 vs. all other). Subject allocation to treatment will be
accomplished by using an interactive web response or interactive
voice response system.
Intervention
Endovascular treatment
The Solitaire device revascularization procedure is summarized in
Fig. 2. Among endovascular arm patients, to facilitate speed of
intervention, two target procedural time targets are employed.
Time from acquisition of the final study-qualifying image (per-
fusion CT or MR sequence prior to Revision F; CT or MRA
sequence under Revision F) to groin puncture is optimally tar-
geted to be less than 70 min and should be no greater than
90 min. Time from groin puncture to first deployment of the
Solitaire device is targeted to be less than 20 min.
For the intervention, the proceduralist may use the Solitaire™
FR device or the Solitaire™ 2 revascularization device. The proper
study device size is selected per device-specific instructions for
use. If deemed appropriate by the neurointerventionalist, IV seda-
tion or general anesthesia may be administered to assure subject
comfort and safety. Several retrieval passes with Solitaire revascu-
larization devices, if needed, may be performed, up to: (1) a
maximum of three retrievals in the same vessel and (2) a
maximum of two retrievals per device.
Procedural angiography
Among subjects randomized to IV tPA + Solitaire device group,
angiography images obtained during the procedure will consist of
the following: (1) Baseline angiogram: obtained prior to device
deployment while assessing the clot location; (2) Post-device use
angiogram: obtained immediately after each pass of study device
use; and (3) Final post-procedural angiogram: obtained after all
treatments have been completed.
CT or MRI
At screening, non-contrast CT (NCCT) or gradient refocused
echo MRI are used to exclude haemorrhage, NCCT or diffusion-
weighted imaging (DWI) MRI to identify early ischemic
changes using the ASPECTS scale, and CT angiography (CTA)
or MRA to assess for target vascular occlusion. In patients trans-
ferred from another facility, updated screening imaging at the
study hospital must be obtained to qualify the patient for the
trial.
At all sites prior to Revision F and with Revision F at sites where
perfusion CT or MR imaging is local standard of care, perfusion
images will also be obtained at screening and will be processed
locally using RApid processing of PerfusIon and Diffusion
(RAPID), an operator-independent system for processing of per-
fusion weighted imaging (PWI) and DWI images (13). RAPID
will generate PWI and DWI maps, segment the PWI and DWI
lesions, and calculate lesion volumes within 10 min of scan
completion.
Follow-up multimodal CT or MRI will be obtained among all
study patients at 27 h (±6 h) from time of randomization to assess
any presence of haemorrhage, recanalization of the occluded
artery, reperfusion of the ischemic region, and infarct growth. At
all sites prior to Revision F and with Revision F at sites where
perfusion CT or MR imaging is local standard of care, perfusion
images will also be acquired at 27 h.
Follow-up and assessment of clinical outcomes
Table 2 shows the schedule of study visits. A 27-h post-
randomization visit includes an NIHSS examination and CT or
MR imaging. Subsequent follow-up visits occur at 7–10 days (or
Table 2 Study visits
Assessment method Screening Procedure
27 h post-
randomization
7–10 days
or discharge
30-day
follow-up
90-day
follow-up
Unscheduled
follow-up
Range 0 0 ± 6 h 0 ± 7 days ± 15 days N/A
Pregnancy test w – – – – – –
Blood labs w – – – – – –
NIH Stroke Scale w – w w w w w
Prestroke modified Rankin Scale w – – – – – –
Modified Rankin Scale – – – w w w w
Barthel Index – – – w – w w
MRI or NCCT w – w – – – –
ASPECTS w – – – – – –
MRA or CTA w – w – – – –
Catheter angiography – w – – – – –
Resource utilization – – – w w w w
EuroQol 5D-5L – – – – w w –
Concomitant medications w w w w w w w
Adverse events w ww w w w w w
Optional: Applicable only to sites with DWI/PWI or CTP imaging as local standard of care at initial evaluation:
PWI MR or CT perfusion w – w – – – –
RAPID imaging processing w – w – – – –
ASPECTS, Alberta Stroke Program Early CT score; CT, computed tomography; CTA, computed tomography angiography; EuroQoL, European Quality
of Life Scale; MR, magnetic resonance; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NCCT, non-contrast computed
tomography; NIH, National Institutes of Health; RAPID, RApid processing of PerfusIon and Diffusion.
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Fig. 2 Solitaire revascularization device procedure. FR, Flow Restoration; FU, follow-up; IFU, instructions for use; TICI, thrombolysis in cerebral infarction.
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discharge if earlier), 30 days, and 90 days, and include the modi-
fied Rankin Scale (mRS) assessing global disability, the Barthel
Index assessing instrumental activities of daily living, the NIHSS
exam assessing neurologic deficit, and the European Quality of
Life Scale (EuroQoL) assessing health-related quality of life. In
addition, to assess health economics outcomes, a Resource Utili-
zation Questionnaire will collect information on use of healthcare
resources through 90 days, including the index hospitalization,
subsequent inpatient and outpatient care, and readmissions.
Adverse event categorization
All adverse events will be validated and categorized for severity
and relatedness by a clinical events committee, comprised of three
expert physicians independent of the investigational sites. Relat-
edness categories will include: (1) study disease-related: event
clearly attributable to underlying disease state with no temporal
relationship to the device, treatment, or medication; (2) concomi-
tant disease-related: event attributable to disease other than the
study disease with no temporal relationship to the device, treat-
ment, or medication; (3) IV tPA-related: event clearly attributable
to IV tPA medication with no temporal relationship to the device
or treatment; (4) procedure-related: event has strong temporal
relationship to the procedure or treatment of the device implan-
tation or any user handling; (5) primary study device-related:
event has a strong temporal relationship to the Solitaire device
and alternative etiology is less likely; (6) ancillary device-related:
any device other than Solitaire™ FR, such as microcatheter or
guidewire; (7) device unknown: device related but unable to attri-
bute a specific device; (8) other; and (9) unknown.
Imaging core laboratory
The Core Imaging Laboratory will provide an independent and
unbiased assessment of imaging-related entry criteria and end-
points. Entry criteria assessed by the Core Lab on initial CT or
MRI will include presence of small core using ASPECTS score,
presence of target penumbral pattern, and presence of proximal
vessel occlusion in the internal carotid artery (ICA) or M1 MCA.
Among endovascular arm patients, the Core Lab will assess the
catheter angiograms for vascular reperfusion following device
use, measured by the thrombolysis in cerebral infarction (TICI)
scale. On 27-h CT or MRI scans, the Core Lab will assess outcome
ASPECTS score, infarct volume, recanalization defined by CTA or
MRA TICI grades, and presence of haemorrhagic transformation.
In patients undergoing perfusion imaging at 27 h, the Core Lab
will assess infarct volume and reperfusion ratio.
Haemorrhages on CT/MRI will be radiologically classified
according to the following categories: HT 1 – small petechiae
within ischemic field without mass effect; HT 2 – confluent pete-
chiae within ischemic field without mass effect; PH1 – hematoma
within ischemic field with some mild space-occupying effect but
involving ≤ 30% of the infarcted area; PH2 – hematoma within
ischemic field with space-occupying effect involving > 30% of the
infarcted area; RIH – any intraparenchymal haemorrhage remote
from the ischemic field; IVH – intraventricular haemorrhage; and
SAH – subarachnoid haemorrhage.
All Core Lab readings will be performed independently by two
experienced readers. For key measures, discrepancies will be
resolved by a third, independent reader. The Core Lab will assess
all CT and MR imaging blinded to treatment assignment. Assess-
ment of catheter angiographic images for revascularization will
not be blinded, as this evaluation will only be done for subjects in
the IV tPA plus Solitaire FR treatment arm.
Primary outcome
The primary study end-point is the degree of disability or depen-
dence at 90 days as assessed by the mRS. A global measure of
disability, the mRS comprises of seven grades ranging from 0 (no
symptoms) to 6 (death). The mRS will be assessed in a formally
operationalized manner by use of the Rankin Focused Assessment
– Ambulation (RFA-A). The 90-day mRS will be assessed by study
personnel certified in the scoring of the mRS using the RFA-A and
will be blinded to treatment assignment.
Secondary outcomes
The study has three secondary clinical efficacy end-points: (1)
death due to any cause at 90 days; (2) functional independence as
defined by mRS score ≤ 2 at 90 days; and (3) change in NIHSS
score at 27 ± 6 h post-randomization.
The study has four technical efficacy end-points: (1) volume
of cerebral infarction as measured by a CT or MRI scan at
27 ± 6 h post-randomization; (2) reperfusion measured by rep-
erfusion ratio on CT or MRI scan 27 ± 6 h post-randomization;
(3) arterial revascularization measured by TICI 2b or 3 following
device use; and (4) correlation of RAPID-assessed core infarct
volume with 27 ± 6 h post-randomization stroke infarction in
subjects who achieved TICI 2b–3 reperfusion without intracra-
nial haemorrhage.
Study safety end-points are: (1) all serious adverse events and
(2) symptomatic intracranial haemorrhage (SICH) at 27 ± 6 h
post-randomization. SICH is defined as any PH1, PH2, RIH,
SAH, or IVH associated with a four-point or more worsening on
the NIHSS within 24 h.
Health economic evaluation end-points will include fea-
tures of care for the index stroke (length of stay, discharge to
home or any other type of facility and cost of that care, reha-
bilitation services, home health services), readmissions due to
subsequent stroke, and calculation of quality-adjusted life year
assessment, using utilities derived from the EuroQoL 5D-5L
assessment. In conjunction with external data on long-term
stroke outcomes, these data will be used to estimate the incre-
mental cost-effectiveness of Solitaire treatment for the target
population.
Sample size
The primary effectiveness end-point in this study is 90-day
global disability assessed via the blinded evaluation of mRS,
analyzed using simultaneous success criteria on: (1) the overall
distribution of mRS (Rankin shift) and (2) the proportion of
subjects achieving functional independence, defined as mRS
of 0 to 2.
The statistical hypothesis on Rankin shift is that the distribu-
tion of mRS in subjects randomized to the IV tPA plus Solitaire
will be more favorable than the distribution in the IV tPA only
group. For this purpose, the entire distribution 0 to 6 of mRS
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values will be considered except that categories 5 and 6 are col-
lapsed into a single group. Additionally, to measure benefit in
terms of functional independence, a simultaneous requirement
for success is that the difference in the proportion of patients with
mRS 0–2 outcomes nominally meets a prespecified minimum
dependent on the evaluable sample size at the time of the
assessment.
Power and sample size are determined by the mRS shift analysis
and are computed by assuming that the true proportions of sub-
jects with various mRS outcomes at the 90-day follow-up visit are
as presented in Table 3. The tPA-only outcome distributions are
those observed with IV tPA use in the two NINDS (National
Institute of Neurologic Disorders and Stroke) tPA trials, restricted
to those subjects with baseline NIHSS of at least 8 but less than 30
to correspond with the current study’s inclusion criteria. The
Solitaire outcome distributions are based on data collected in
heterogeneous settings including the use and non-use of IV tPA.
Included in these rates is adjustment for an expected proportion
of 10% of subjects randomized to the Solitaire group who will be
unable for anatomical reasons to be treated with the randomized
device; this cohort of subjects will remain in the Solitaire group
per intent to treat but are assumed to have outcomes similar to
those randomized to tPA only.
Sample size and power are computed incorporating a
group sequential analysis plan with five interim analyses for
efficacy, futility, and safety. Under this group sequential
analysis plan, with a one-sided alpha level set at 0·025, 750 sub-
jects with an evaluable primary endpoint provide 90% power
for testing the study’s primary effectiveness hypothesis; assum-
ing attrition of 10% for the primary end-point, the total ran-
domized sample size is up to 833 while the expected randomized
sample size under the alternative hypothesis is approximately
477 (Table 4).
Statistical analyses
Statistical testing of the primary end-point will be conducted
using the Cochran–Mantel–Haenszel test for the shift in Rankin
scores, augmented by the requirement of functional indepen-
dence cited above. Type I and Type II error will be computed via
simulation and overall alpha will be controlled at a one-sided level
of 0·025.
The primary end-point analysis and the testing strategy based
on the group sequential design will be conducted using the inten-
tion to treat (ITT) population. If the results are favorable, a
second analysis of the primary end-point will be conducted using
the Food and Drug Administration (FDA) evaluable cohort
(those having received IV tPA within three-hours of stroke
symptom onset) following a step-down approach.
Group Sequential Analysis: Interim analyses will be performed
when 200 subjects from the ITT population have provided evalu-
able primary effectiveness data and then after each subsequent
100 subjects, to a maximum of 750 subjects with evaluable data
(i.e. 200, 300, 400, 500, 600, and 750). Table 4 provides the group
sequential boundaries including minimum acceptable statistical
criteria at each look (including the final analysis). Additionally, a
safety stopping rule is defined under which the trial is halted for a
substantial mortality difference in either possible direction at the
various interim looks. This rule does not impact effectiveness
findings.
Study organization and funding
Study conduct is overseen by the executive and steering commit-
tees and the sponsor. The executive committee will be led by the
global principal investigator (PI) and will include a global
imaging and workflow PI, an EU (European Union) national PI,
US and EU interventional PIs, and an interventional advisor. The
steering committee will be comprised of recognized experts in the
Table 3 Hypothesized true outcomes for sample size calculations
Randomized group mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5–6
Solitaire plus IV tPA 19·7% 18·2% 18·3% 9·4% 12·5% 21·9%
IV tPA alone 11·0% 21·6% 8·1% 15·7% 14·4% 29·2%
IV, intravenous; mRS, modified Rankin Scale; tPA, tissue plasminogen activator.
Table 4 Group sequential analysis
Evaluable
sample size
Stopping for safety Stopping for efficacy Stopping for futility
Two-sided alpha
for mortality
Two-sided alpha
for Rankin shift
Effect size Δ
for mRS 0–2
Effect size φ for
mRS mean value
Effect size Δ
for mRS 0–2
200 0·0036 0·0200 12·0% 0·00 0·0%
300 0·0058 0·0125 10·0% 0·00 0·0%
400 0·0094 0·0150 9·0% 0·10 n/a
500 0·0147 0·0150 8·0% 0·14 n/a
600 0·0203 0·0150 6·0% 0·14 n/a
750 (final) 0·0340 0·0350 5·0% n/a n/a
mRS, modified Rankin Scale.
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treatment of stroke and representatives from leading enrolling
sites. The executive committee, assisted by the steering committee,
will oversee all clinical trial activities including protocol develop-
ment and protocol amendment during study conduct. Covidien is
the study sponsor and source of funding, and will perform moni-
toring at each site to ensure protection of the rights of subjects,
the safety of subjects, and the quality and integrity of the data
collected and submitted according to FDA and EMA (European
Medicines Agency) regulation.
Data Safety Monitoring Board
The Data Safety Monitoring Board will be comprised of individu-
als who are independent of the investigational sites and who
have expertise in multiple disciplines, including neurology,
neurosurgery, interventional neuroradiology, and biostatistics/
epidemiology. The independence of the members will be main-
tained and bias minimized by blinding, to the extent possible, all
members to individual subject and treating center identity when
reviewing study data. This board shall provide recommendations
to the sponsor regarding stopping/continuing enrollment in the
study, including carrying out planned formal interim analyses.
Discussion
The SWIFT PRIME trial will provide definitive information on
the efficacy and safety of the Solitaire revascularization devices
when added to IV tPA, in comparison with therapy with IV tPA
alone. The study was designed to incorporate lessons from trials
of earlier generation endovascular interventions that failed to
demonstrate treatment benefit (14–17). Unlike those prior
studies, SWIFT PRIME tests a highly effective recanalization
device, the Solitaire stent retriever, which achieves recanalization
much more frequently and rapidly than earlier generation thera-
pies (9). SWIFT PRIME ensures that all enrolled patients have
appropriate target occlusions by mandating CTA or MRA
imaging at entry. SWIFT PRIME is enrolling only patients with
occlusion locations that are distinctively responsive to endovas-
cular therapy, by including ICA and M1 MCA lesions that
respond poorly to IV tPA and excluding M2 and more distal MCA
lesions that frequently benefit from IV tPA alone. SWIFT PRIME
is identifying patients who have salvageable brain left to save at
the time of enrollment by requiring small core size on ASPECTS
or RAPID imaging. SWIFT PRIME is ensuring that all patients
who clinicians expect may respond to therapy will be enrolled by
requiring that sites commit to enroll all eligible study patients.
SWIFT PRIME is minimizing progression of infarct that occurs
during delays between the time of study enrollment and endovas-
cular reperfusion through rigorous focus on management effi-
ciency and intensive quality improvement, training, and feedback
about interventional workflow during the trial. Lastly, SWIFT
PRIME is providing equivalent concomitant therapy in the two
treatment arms, using full-dose tPA in both study groups, rather
than a reduced dose in the neuroendovascular arm.
SWIFT PRIME enrolled its first patient on December 30, 2012.
When completed, SWIFT PRIME will provide pivotal data allow-
ing assessment of the efficacy and safety of the Solitaire revascu-
larization device for reperfusion of AIS caused by large
intracranial vessel occlusion.
Study personnel
Global PI
Jeffrey L. Saver, MD
Executive committee
Hans-Christoph Diener, MD (EU PI), Mayank Goyal, MD (global
imaging and workflow PI), Elad Levy, MD (US interventional PI),
Alain Bonafé, MD (EU interventional PI), Vitor Mendes Pereira,
MD (EU interventional PI), and Reza Jahan, MD (interventional
advisor)
Steering committee
Gregory W. Albers, MD (global penumbral imaging investigator),
Christophe Cognard, MD, David Cohen, MD, Werner Hacke, MD,
Olav Jansen, MD, Tudor G. Jovin, MD, Heinrich P. Mattle, MD,
Raul G. Nogueira, MD, Adnan H. Siddiqui, MD, and DiLeep R.
Yavagal, MD
Data safety and monitoring committee
Rüdiger von Kummer, MD (chair), Wade Smith, MD, Francis
Turjman, MD, and Scott Hamilton, PhD
Clinical events committee
Arun Amar, MD (chair), Nerses Sanossian, MD, and Yince Loh,
MD
Site investigators and coordinators
S. Starkman, MD (PI), J. Guzy (UCLA/Ronald Reagan UCLA
Medical Center); W. Clark, MD (PI), S. Jamieson (Oregon Health
and Science University); V. Reddy, MD (PI), L. Baxendell (Univer-
sity of Pittsburgh Medical Center); A. Siddiqui, MD (PI), S. Hall
(University of Buffalo Neurosurgery/Buffalo General Hospital);
D. Yavagal, MD (PI), K. Ramdas (University of Miami/Jackson
Memorial Hospital); T. Devlin, MD (PI), K. Barton (Chattanooga
Center for Neurologic Research/Erlanger Hospital); B. Jagadee-
san, MD (PI), D. Hildebrandt (Hennepin Country Medical
Center); B-F. Fitzsimmons, MD (PI), T. Larson (Medical College
of Wisconsin/Froedtert Memorial Lutheran Hospital); R. Ecker,
MD (PI), L. Connolly (Maine Medical Center); R. Budzik, MD
(PI), M. Taylor (Ohio Health Research Institute/Riverside Meth-
odist Hospital); I. Acosta, MD (PI), E. Bonwit (Florida Hospital);
E. Deshaies, MD (PI), M. Villwock (State University of New York
Upstate); M. Jumaa, MD (PI), T. Hendrickson (Promedica Toledo
Hospital); C. Ramsey, MD (PI), S. Renfrow (Central Baptist Hos-
pital); M.S. Hussain, MD (PI), A. Richmond (Cleveland Clinic
Cerebrovascular Center, NI); J. Carpenter, MD (PI), J. Domico
(West Virginia University Hospital); V. Deshmukh, MD (PI), M.
Rodriguez (Providence Brain and Spine Institute); A. Puri, MD
(PI), M. Howk (University of Massachusetts Medical Center); R.
Nogueira, MD (PI), S. Doppelheuer (Emory University/Grady
Medical Center); D. Lopes, MD (PI), C. Anton (Rush University
Medical Center); C. Martin, MD (PI), B. Brion (Saint Luke’s
Hospital); H. Farid, MD (PI), L. Cross (St. Jude Medical Center);
A. Hassan, DO (PI), L. Jones-Fullingim (Valley Baptist Medical
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Center-Harlingen); A. Malek, MD (PI), M. Smith, P. Beck (Tenet
Health Systems); A. Bonafé, MD (PI), M. Moynier (CHU de
Montpellier – Hôpital Gui de Chauliac); O. Jansen, MD (PI), S.
Krieter (Universitätsklinikum Kiel- Abteilung für Neuroradiolo-
gie); JF. Arenillas, MD (PI), FJ Reyes Muñoz (Hospital Clinico
Universitario de Valladolid); R. du Mesnil de Rochemont, MD
(PI), H. Braun (Klinikum der Johann Wolfgang Goethe-
Universität); L. Remonda, MD (PI), M. Guglielmetti
(Kantonsspital Aarau); C. Weimar, MD (PI), M. Dietzold
(Universitätsklinikum Essen); K. Hansen, MD (PI), T. Hyldal
(Rigshospitalet, Copenhagen University Hospital); P. Papanag-
iotou, MD (PI), H. Merdivan (Klinikum Bremen-Mitte); M.
Killer-Oberpfalzer, MD (PI), A. Jedlitschka (Universitätsklinikum
Christian Doppler Klinik Salzburg); P. Ringleb, MD (PI), I.
Ludwig (Universitätsklinikum Heidelberg/ Neurologische Klinik
und Poliklinik); G. Reimann, MD (PI), K. Burg (Klinikum Dort-
mund); C. Brekenfeld, MD (PI), G. Wortmann (Universitätsklini-
kum Hamburg-Eppendorf); S. Prothmann, MD (PI), B.
Schwaiger (Klinikum rechts der Isar – Technische Universität
München); H-P Haring, MD (PI), K. SØrensen (Landes-
Nervenklinik Wagner-Jauregg); and G. Andersen, MD (PI), E.
Bach (Aarhus University Hospital)
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